These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 7325301)

  • 1. Central cardiovascular effects of flutonidine in adult fowls.
    Marmo E; Di Mezza F; Nistico G; Somma A; Ariello B; Imperatore A
    Agressologie; 1981; 22(6):269-72. PubMed ID: 7325301
    [No Abstract]   [Full Text] [Related]  

  • 2. Cardiovascular effects of flutonidin after acute oral administration.
    Mazzola C; Guffanti E; Ferrario N
    Farmaco Prat; 1981 May; 36(5):262-70. PubMed ID: 7238849
    [No Abstract]   [Full Text] [Related]  

  • 3. [The acute effect of ST-155 hypotensive agent, on cardiac and renal hemodynamics].
    Vorburger C; Bütikofer E; Weiss S; Diacon C
    Helv Med Acta; 1967; 34(1):Suppl:133-4. PubMed ID: 5589186
    [No Abstract]   [Full Text] [Related]  

  • 4. Angiotensin II receptors and angiotensin II receptor antagonists.
    Timmermans PB; Wong PC; Chiu AT; Herblin WF; Benfield P; Carini DJ; Lee RJ; Wexler RR; Saye JA; Smith RD
    Pharmacol Rev; 1993 Jun; 45(2):205-51. PubMed ID: 8372104
    [No Abstract]   [Full Text] [Related]  

  • 5. [Cerebral hemodynamics under the effect of 2-(2,6-dichlorphenylamino)-2-imidazoline hydrochloride].
    Deisenhammer E; Klausberger EM
    Arzneimittelforschung; 1966 Sep; 16(9):1161-2. PubMed ID: 6014734
    [No Abstract]   [Full Text] [Related]  

  • 6. Substituted aryl-tetrahydro-pyrrolo imidazoles: a new class of centrally acting antihypertensives [proceedings].
    Clough DP; Hatton R; Pettinger SJ; Samuels GM; Shaw A
    Br J Pharmacol; 1978 Mar; 62(3):385P-386P. PubMed ID: 638323
    [No Abstract]   [Full Text] [Related]  

  • 7. Pharmacology and clinical use of moxonidine, a new centrally acting sympatholytic antihypertensive agent.
    Prichard BN; Owens CW; Graham BR
    J Hum Hypertens; 1997 Aug; 11 Suppl 1():S29-45. PubMed ID: 9321737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effect of moxonidine monotherapy and in combination with melatonin on hemodynamic parameters in patients with arterial hypertension].
    Zaslavskaia RM; Komarov FI; Shakirova AN; Teĭblium MM; Akhmetov KZh
    Klin Med (Mosk); 2000; 78(4):41-4. PubMed ID: 10833890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute myocardial and vascular responses to specific angiotensin II antagonism in the spontaneously hypertensive rat.
    Cody RJ; Binkley PF; Haas GJ; Brown DM
    Am J Hypertens; 1995 May; 8(5 Pt 1):500-8. PubMed ID: 7662227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Testing of antihypertensive agents with prolonged effect].
    Formanek K; Lindner A; Selzer H
    Wien Klin Wochenschr; 1968 Mar; 80(10):185-91. PubMed ID: 4967834
    [No Abstract]   [Full Text] [Related]  

  • 11. Antihypertensive pharmacological agents: beyond their lowering blood pressure effects.
    Miatello RM
    Cell Mol Biol (Noisy-le-grand); 2005 Nov; 51(6):521-3. PubMed ID: 16309575
    [No Abstract]   [Full Text] [Related]  

  • 12. [Moxonidine. A new antihypertensive agent of central action].
    Leães CG; Rosito GA
    Arq Bras Cardiol; 1998 Jun; 70(6):443-8. PubMed ID: 9713089
    [No Abstract]   [Full Text] [Related]  

  • 13. [A new antihypertensive drug: clonidine or Catapressan].
    Amery A; Bossaert H; Deruyttere M; Verstreken G
    Acta Clin Belg; 1969; 24(6):334-55. PubMed ID: 4923381
    [No Abstract]   [Full Text] [Related]  

  • 14. Influence of central inhibition of sympathetic nervous activity on myocardial metabolism in chronic heart failure: acute effects of the imidazoline I1-receptor agonist moxonidine.
    Mobini R; Fu M; Jansson PA; Bergh CH; Scharin Täng M; Waagstein F; Andersson B
    Clin Sci (Lond); 2006 Mar; 110(3):329-36. PubMed ID: 16209659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Catapresan. A new antihypertensive drug].
    Naess K; Lund-Larsen PG
    Tidsskr Nor Laegeforen; 1970 Feb; 90(4):416-9. PubMed ID: 5426474
    [No Abstract]   [Full Text] [Related]  

  • 16. The advantages of angiotensin II antagonism.
    Burnier M; Waeber B; Brunner HR
    J Hypertens Suppl; 1994 Jul; 12(2):S7-15. PubMed ID: 7965267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Involvement of central alpha1- and alpha2-adrenoceptors on cardiovascular responses to moxonidine.
    Moreira TS; Takakura AC; Menani JV; Colombari E
    Eur J Pharmacol; 2007 Jun; 563(1-3):164-71. PubMed ID: 17382316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular effects of novel imidazoline congeners.
    Shukla S; Bhalla M; Misra U; Mukerjee D; Saxsena AK; Sinha JN; Shanker K
    Boll Chim Farm; 1998; 137(7):229-32. PubMed ID: 9795479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discordant effects of beta-blockade on central aortic systolic and brachial systolic blood pressure: considerations beyond the cuff.
    Epstein BJ; Anderson S
    Pharmacotherapy; 2007 Sep; 27(9):1322-33. PubMed ID: 17723086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effects of an angiotensin II receptor antagonist (valsartan) on macro- and microcirculatory hemodynamics of the arm in hypertensive patients].
    Marchi SD; Prior M; Zannoni M; Lucchese L; Arosio E
    Minerva Cardioangiol; 1999 Dec; 47(12):554-6. PubMed ID: 10670200
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.